This article was originally published in Start Up
SOVAmed, a technology spin-off from the University of Koblenz-Landau in Germany, develops visualization and analysis tools that support vascular surgeons and interventional radiologists. SOVAmed's lead application, SOVA.evar, is designed to detect AAAs and evaluate clinically significant parameters more accurately and rapidly than existing technologies.
You may also be interested in...
Abingworth's Bet On Lombard: Best Of Both Worlds For VCs
As venture investing in medical devices continues to split between early- and late-stage deals, investors increasingly face a choice: early-stage deals, where valuations are low, but risk is high and timelines are generally long; and late-stage opportunities, where risk is lower and timelines shorter, but the valuations are much higher. What if you could find an opportunity with the timelines and risk profile of a late-stage deal, at the valuation of an early-stage deal? That's what investors at Abingworth believe they've found in Lombard Medical Technologies PLC, a company with a novel approach to endovascular abdominal aortic aneurysm repair.
Aptus Endosystems Inc.
Despite notable advances in endovascular aortic aneurysm repair systems to prevent aneurysm rupture by stent-graft implantation, between 15-20% of patients eventually require secondary intervention to address endograft failures. Aptus Endosystems hopes to dramatically reduce the incidence of secondary intervention with its EVAR system: a low-profile modular endograft which uses novel stapling fixation that the company says approaches the durability of open surgery and makes minimally invasive AAA treatment an option for more patients, even those with challenging anatomy.
Endoluminal Sciences Pty Ltd.
Endoluminal Sciences has developed a polymer-based "active sealing" technology called ELS SEAL that can be applied to existing EVAR devices to enhance the long-term durability of the seal against the vessel wall, without increasing the device profile or impacting established delivery techniques. Its "bolt-on" technology aims to address the lethal failure mode of EVAR systems, endoleaks, as well as open up EVAR treatment to the 40% of patients who are not currently candidates for the procedure.